Lucia Mori

Company: Matterhorn Biosciences

Job title: Founding Chief Scientific Officer

Seminars:

Antigen-Specific Targeting of Tumours Across MHC Barriers 8:30 am

• Looking beyond peptide antigens in tumour therapy • The advantages of targeting oligomorphic antigenpresenting molecules • The advantages of adoptive cell therapies based on MR1- restricted TCRs specific for tumour-associated metabolites, and CD1c-restricted TCRs specific for a leukaemiaassociated lipid antigenRead more

day: Day One

Workshop C: Antigen-Specific Targeting of Tumours Across MHC Barriers 3:00 pm

Looking beyond peptide antigens in tumour therapy The advantages of targeting oligomorphic antigen-presenting molecules The advantages of adoptive cell therapies based on MR1- restricted TCRs specific for tumour-associated metabolites, and CD1c-restricted TCRs specific for a leukaemia-associated lipid antigenRead more

day: Workshop - Track A - Evening